Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
about
Treatment of liver metastases in patients with neuroendocrine tumors of gastroesophageal and pancreatic originSynthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.Progress in the treatment of neuroendocrine tumors.(68)Ga-labeled radiopharmaceuticals for positron emission tomography.New treatment options for patients with advanced neuroendocrine tumors.Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.Nuclear medicine applications in molecular imaging.Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.Targeted therapy in advanced well-differentiated neuroendocrine tumors.From basic to clinical research in gastroenteropancreatic neuroendocrine tumor disease -- the clinician-scientist perspective.A functional comparison of recombinant and native somatostatin sst2 receptor variants in epithelia.Stroma targeting nuclear imaging and radiopharmaceuticals.[111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical studyDesign of radiolabelled ligands for the imaging and treatment of cancer.Emerging therapies for the treatment of patients with advanced neuroendocrine tumors.Somatostatin receptor scintigraphy in thoracic diseases.Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.Clinical utility of indigenously formulated single-vial lyophilized HYNIC-TOC kit in evaluating Gastro-entero Pancreatic neuro endocrine tumours.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumorsBaseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.Targeting somatostatin receptors using in situ-bioconjugated fluorescent nanoparticles.Radiolabeled peptides: valuable tools for the detection and treatment of cancerMetal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting.The effect of purification of Ga-68-labeled exendin on in vivo distribution.Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects.Somatostatin analogues labeled with copper radioisotopes: current status.The role of somatostatin receptor scintigraphy on the diagnosis of desmoid tumors.Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- zation as well as Tumor Cells in Molecular Tumor ImagingThe 68Ge/ 68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine?Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer.Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.Modeling combined radiopharmaceutical therapy: a linear optimization framework.111In-pentetreotide scintigraphy in medulloblastoma: a comparison with magnetic resonance imaging.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureDevelopment of Targeting Ligands for HER2 Receptor: Simplified Receptor Model Employed for Selecting Highly Specific Molecules
P2860
Q21296729-7CD314F3-8320-4E0A-B849-4B7293FBC478Q30574451-A8EA3C35-0B6E-40E6-9DB8-B65DC0A64BA2Q33643643-E7D32D67-6F7F-41EE-B04E-3429E0D975A4Q33704038-440755B3-7A9D-4892-9F92-2A337D9AE37EQ34173336-BEA4A4C4-6924-4127-9E95-3F0D9C3587E0Q34743520-5952E477-8617-42AF-AB09-E8A22C093F93Q34918545-CFF8E66B-3EB0-4054-8993-4994BCF02D30Q35020349-22381887-5586-445A-A5F0-B6BA804E2F8AQ35087810-0E1519E9-D528-4C51-87A3-CB9997770ABDQ35584497-427905F6-6946-4DA2-AAB0-A00174AFE2D2Q35915032-69CDAD1B-72AF-4BE4-BDDD-BE0E57DD2A90Q35995226-70E72D5C-C630-433A-892E-5C36F57D9388Q35999606-5BD58363-90BF-46DD-8C1E-471DB25910A8Q36125639-1E2F35A7-31EF-477D-83A9-E331AFEC81DBQ36704588-802185B2-D3CA-4C81-9981-1ABE5A057D70Q36866607-C523CBEE-B6B0-4FCD-BD21-ACAD74A3923FQ37030460-5770CF1D-1804-4441-A738-DB09E0576F40Q37040004-58AB25CC-A353-4F0B-B020-AFFB467AC26DQ37077358-5D42DEAF-C928-467C-9A9A-2BF94C7D80C6Q37083440-5AB761F7-6CE2-453F-97AB-09A07CFFD886Q37454406-9EC28629-CB02-48C5-AD0A-F79A474BBD9DQ37889407-4B6032EF-EA27-4497-AC05-F924E3D23B26Q38769465-2C52E5EE-2AC2-4842-887C-0DA1AB6F430EQ38870046-049890E2-A3D9-42D1-A95A-11218AE178EFQ39311877-DA1B7503-D88C-494E-B5F7-02F9CE3F555CQ39596344-0540E8E2-0FDF-437E-A63B-2E8D359F1D1DQ40017086-E995EB04-5FA6-470E-B311-BF6AE67D821CQ41726979-13DF9E75-C513-487E-8EE7-BC132A5E1CCEQ41896043-E805B5A5-E3D0-4AFA-8365-A2A02CC65A71Q42133416-5CBB0530-1094-4313-AEEB-A47F025A880FQ42186533-F32D4ABB-5E80-40E6-B22C-CC7B2D22180AQ42573080-77AB912C-C2F2-4032-BE06-C6973E98020AQ42594589-14201580-9283-4AFC-85F1-407E85C8FEE7Q42611383-3DCA6260-E9EF-4768-88EF-EF44C26D9EDAQ43260540-540963D2-A6E8-467C-9DC3-6544FE40A1D6Q44377511-A3EEDD1B-7D00-46B9-881B-F03D24B13AE1Q46149964-0EB3ACE0-4407-4FDB-8478-8F61E2CC2D68Q48200381-6A6CB056-E4BD-469B-A72F-7C0A829A80E6Q57144951-ECB7AA92-0F60-4F37-BC57-2F5E463B810BQ57599812-568EDA22-07FD-4AA1-8182-85DE4BAC5CC8
P2860
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Somatostatin receptor-mediated ...... tions and future perspectives.
@ast
Somatostatin receptor-mediated ...... tions and future perspectives.
@en
Somatostatin receptor-mediated ...... tions and future perspectives.
@nl
type
label
Somatostatin receptor-mediated ...... tions and future perspectives.
@ast
Somatostatin receptor-mediated ...... tions and future perspectives.
@en
Somatostatin receptor-mediated ...... tions and future perspectives.
@nl
prefLabel
Somatostatin receptor-mediated ...... tions and future perspectives.
@ast
Somatostatin receptor-mediated ...... tions and future perspectives.
@en
Somatostatin receptor-mediated ...... tions and future perspectives.
@nl
P2093
P356
P1476
Somatostatin receptor-mediated ...... tions and future perspectives.
@en
P2093
Breeman WA
Krenning EP
Kwekkeboom DJ
P2888
P304
P356
10.1007/S002590100502
P577
2001-09-01T00:00:00Z